Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The two cyclooxygenase (COX) enzymes catalyze the oxygenation of arachidonic acid to prostaglandin endoperoxides, which are the common intermediates in the biosynthesis of the bioactive lipids prostaglandins and thromboxane. COX-1 and COX-2 are ∼60% identical in amino acid sequence, exhibit highly homologous three-dimensional structures, and appear functionally similar at the biochemical level. Recent work has uncovered a subtle functional difference between the two enzymes, namely the ability of COX-2 to efficiently utilize neutral derivatives (esters and amides) of arachidonic acid as substrates. Foremost among these neutral substrates are the endocannabinoids 2-arachidonoylglycerol and arachidonoylethanolamide. This raises the possibility that COX-2 oxygenation plays a role in a novel signaling pathway dependent on agonist-induced release of endocannabinoids and their selective oxygenation by COX-2. Among the products of COX-2 oxygenation of endocannabinoids are glyceryl prostaglandins, some of which (e.g. glyceryl prostaglandin E2 and glyceryl prostaglandin I2) exhibit interesting biological activities in inflammatory, neurological, and vascular systems. These compounds are produced in intact cells stimulated with physiological agonists and have been isolated from in vivo sources. Important concepts relevant to the hypothesis of a COX-2-selective signaling pathway are presented. The two cyclooxygenase (COX) enzymes catalyze the oxygenation of arachidonic acid to prostaglandin endoperoxides, which are the common intermediates in the biosynthesis of the bioactive lipids prostaglandins and thromboxane. COX-1 and COX-2 are ∼60% identical in amino acid sequence, exhibit highly homologous three-dimensional structures, and appear functionally similar at the biochemical level. Recent work has uncovered a subtle functional difference between the two enzymes, namely the ability of COX-2 to efficiently utilize neutral derivatives (esters and amides) of arachidonic acid as substrates. Foremost among these neutral substrates are the endocannabinoids 2-arachidonoylglycerol and arachidonoylethanolamide. This raises the possibility that COX-2 oxygenation plays a role in a novel signaling pathway dependent on agonist-induced release of endocannabinoids and their selective oxygenation by COX-2. Among the products of COX-2 oxygenation of endocannabinoids are glyceryl prostaglandins, some of which (e.g. glyceryl prostaglandin E2 and glyceryl prostaglandin I2) exhibit interesting biological activities in inflammatory, neurological, and vascular systems. These compounds are produced in intact cells stimulated with physiological agonists and have been isolated from in vivo sources. Important concepts relevant to the hypothesis of a COX-2-selective signaling pathway are presented. Cyclooxygenases (COX-1 and COX-2) 2The abbreviations used are:COXcyclooxygenase (prostaglandin G/H synthase)AAarachidonic acidPGprostaglandinPGI2prostacyclinRPMsresident peritoneal macrophagesLPSlipopolysaccharideAEAarachidonoylethanolamide2-AG2-arachidonoylglycerolPG-Gglyceryl prostaglandinPG-EAethanolamide prostaglandinIP3inositol 1,4,5-trisphosphateERKextracellular signal-regulated kinasemIPSCsminiature inhibitory postsynaptic currentsEP receptorE series PG receptorMAPKmitogen-activated protein kinaseILinterleukinFP receptorF series PG receptorPPARδperoxisome proliferator-activated receptor-δsiRNAsmall interfering RNADAGdiacylglycerolPLphospholipase. 2The abbreviations used are:COXcyclooxygenase (prostaglandin G/H synthase)AAarachidonic acidPGprostaglandinPGI2prostacyclinRPMsresident peritoneal macrophagesLPSlipopolysaccharideAEAarachidonoylethanolamide2-AG2-arachidonoylglycerolPG-Gglyceryl prostaglandinPG-EAethanolamide prostaglandinIP3inositol 1,4,5-trisphosphateERKextracellular signal-regulated kinasemIPSCsminiature inhibitory postsynaptic currentsEP receptorE series PG receptorMAPKmitogen-activated protein kinaseILinterleukinFP receptorF series PG receptorPPARδperoxisome proliferator-activated receptor-δsiRNAsmall interfering RNADAGdiacylglycerolPLphospholipase. catalyze the committed step in the conversion of AA to PGs, thromboxane, and PGI2 and, in so doing, trigger the biosynthesis of an important family of lipid mediators (1Smith W.L. DeWitt D.L. Garavito R.M. Annu. Rev. Biochem. 2000; 69: 145-182Crossref PubMed Scopus (2394) Google Scholar, 2Hata A.N. Breyer R.M. Pharmacol. Ther. 2004; 103: 147-166Crossref PubMed Scopus (664) Google Scholar). Cyclooxygenase activity was first described in 1964 (3Bergstrom S. Danielsson H. Samuelsson B. Biochim. Biophys. Acta. 1964; 90: 207-210Crossref PubMed Scopus (10) Google Scholar), and COX-1 was purified in 1976 (4Miyamoto T. Ogino N. Yamamoto S. Hayaishi O. J. Biol. Chem. 1976; 251: 2629-2636Abstract Full Text PDF PubMed Google Scholar). These events occurred concomitantly with the realization that nonsteroidal anti-inflammatory drugs achieve their anti-inflammatory effects primarily by blocking the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310
Kozak, K. R., Rowlinson, S. W., & Marnett, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007088200 · Cited by 390
Kozak, K. R., Crews, B. C., Morrow, J. D., Wang, L.-H., Ma, Y. H., Weinander, R., Jakobsson, P.-J., & Marnett, L. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206788200 · Cited by 368
Self-citationSang, N., Zhang, J., & Chen, C. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.105569 · Cited by 89
Cited by
Eicosanoid storm in infection and inflammation
Dennis, E. A., & Norris, P. C. (2015) · Nature Reviews Immunology · doi:10.1038/nri3859 · Cited by 1,517
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Cyclooxygenases: structural and functional insights
Rouzer, C. A., & Marnett, L. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800042-jlr200 · Cited by 688
Self-citationIannotti, F. A., Di Marzo, V., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357
Threatened by mining, polymetallic nodules are required to preserve abyssal epifauna
Vanreusel, A., Hilario, A., Ribeiro, P. A., Menot, L., & Arbizu, P. M. (2016) · Scientific Reports · doi:10.1038/srep26808 · Cited by 302
Metadata
- Authors
- Rouzer, C. A., & Marnett, L. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 283
- Issue
- 13
- Pages
- 8065-8069
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1987131861
- Cited by
- 117
- References
- 7
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.